Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Vilas, Javier A.
dc.contributor.authorPino-Ángeles, Almudena
dc.contributor.authorMartínez-Póveda, Beatriz Amparo 
dc.contributor.authorRodríguez-Quesada, Ana María 
dc.contributor.authorMedina-Torres, Miguel Ángel 
dc.date.accessioned2017-10-13T09:41:12Z
dc.date.available2017-10-13T09:41:12Z
dc.date.created2016-10-25
dc.date.issued2017-01
dc.identifier.citationCancer Letters 358 (2017) 1-11es_ES
dc.identifier.urihttp://hdl.handle.net/10630/14631
dc.descriptionEste es el manuscrito que fue aceptado y que finalmente se publicó en Cancer Letters con el DOI: 10.1016/j.canlet.2016.10.037es_ES
dc.description.abstractThe natural bioactive compound damnacanthal inhibits several tyrosine kinases. Herein, we show that -in fact- damancanthal is a multi kinase inhibitor. A docking and molecular dynamics simulation approach allows getting further insight on the inhibitory effect of damnacanthal on three different kinases: vascular endothelial growth factor receptor-2, c-Met and focal adhesion kinase. Several of the kinases targeted and inhibited by damnacanthal are involved in angiogenesis. Ex vivo and in vivo experiments clearly demonstrate that, indeed, damnacanthal is a very potent inhibitor of angiogenesis. A number of in vitro assays contribute to determine the specific effects of damnacanthal on each of the steps of the angiogenic process, including inhibition of tubulogenesis, endothelial cell proliferation, survival, migration and production of extracellular matrix remodeling enzyme. Taken altogether, these results suggest that damancanthal could have potential interest for the treatment of cancer and other angiogenesisdependent diseases.es_ES
dc.description.sponsorshipSupported by grants BIO2014-56092-R (MINECO and FEDER), P12-CTS-1507 (Andalusian Government and FEDER) and funds from group BIO-267 (Andalusian Government). The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain). JAGV had the financial support of Vicerrectorado de Investigación y Transferencia (University of Málaga, Spain). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectCanceres_ES
dc.subject.otherMorinda citrifoliaes_ES
dc.subject.otherDamnacanthales_ES
dc.subject.otherNonies_ES
dc.subject.otherAngiogenesises_ES
dc.subject.otherMulti-Kinase inhibitores_ES
dc.titleThe noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effectses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Cienciases_ES
dc.rights.ccby-nc-nd
dc.type.hasVersioninfo:eu-repo/semantics/submittedVersiones_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem